Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare and technology leaders.
Full Quick Take
Oakmark's U.S. Concentrated Strategy posted a solid 3.87% net return in Q2 2025, outpacing its value benchmark, and used market pullbacks to aggressively buy beaten-down healthcare and technology leaders.
